The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Open Access
- 17 December 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 4 (1), 1-14
- https://doi.org/10.1038/s41392-019-0099-9
Abstract
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient’s tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.Keywords
This publication has 156 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- RETRACTED ARTICLE: EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancersNature Medicine, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Protein inhibitor of activated STAT3 expression in lung cancerMolecular Oncology, 2011
- The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeuticsSeminars in Cell & Developmental Biology, 2010
- The biology and treatment of EML4-ALK non-small cell lung cancerEuropean Journal of Cancer, 2010
- Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature, 2007
- EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain DimerizationMolecular Cell, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular DomainsCell, 2002